Unlock Dual-Action Power for Type 2 Diabetes Management

Introducing Mounjaro (Tirzepatide), a groundbreaking, once-weekly injectable medication designed to be a powerful adjunct to diet and exercise in adults with Type 2 Diabetes Mellitus. Mounjaro is the first and only FDA-approved therapy that activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This unique dual-agonism approach helps your body manage blood sugar levels more effectively than ever before.

The Innovation of Dual-Action

Tirzepatide’s novel mechanism works to improve glycemic control by:

• Stimulating Insulin Release: Only when blood sugar is high, providing targeted control.

• Reducing Glucagon Production: Limiting the amount of sugar released by the liver.

• Slowing Gastric Emptying: Promoting a lasting feeling of fullness, which can significantly support weight management efforts.

By targeting these two key pathways, Mounjaro offers a comprehensive approach to metabolic health that goes beyond traditional treatments.

Simple, Consistent Dosing

The Mounjaro pre-filled injection pens (often referred to as KwikPens) make your weekly dosing routine simple and virtually effortless. Each strength is color-coded for clarity (as seen in the image, featuring doses from 2.5 mg to the maximum 15 mg), ensuring you administer your prescribed dose accurately. The pens are designed for a comfortable, once-weekly subcutaneous injection into the abdomen, thigh, or upper arm.

Product Highlights:

• Active Ingredient: Tirzepatide

• Dosing Frequency: Once per week

• Available Strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg

• Delivery System: Pre-filled, easy-to-use injection pen (KwikPen)

Important Safety Information: It is not for use in patients with Type 1 Diabetes Mellitus. Please consult your healthcare provider to determine if Mounjaro is right for your treatment plan, and review all prescribing information, including risks and side effects, before use.